345 related articles for article (PubMed ID: 35371055)
21. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
[TBL] [Abstract][Full Text] [Related]
22. Factors regulating apoptosis and homeostasis of CD4+ CD25(high) FOXP3+ regulatory T cells are new therapeutic targets.
Yang XF
Front Biosci; 2008 Jan; 13():1472-99. PubMed ID: 17981643
[TBL] [Abstract][Full Text] [Related]
23. Understanding and Targeting Human Cancer Regulatory T Cells to Improve Therapy.
Kolb HR; Borcherding N; Zhang W
Adv Exp Med Biol; 2021; 1278():229-256. PubMed ID: 33523451
[TBL] [Abstract][Full Text] [Related]
24. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
25. Rubiginosin B selectively inhibits Treg cell differentiation and enhances anti-tumor immune responses by targeting calcineurin-NFAT signaling pathway.
Geng CA; Chen FY; Zheng JB; Liao P; Li TZ; Zhang XM; Chen X; Chen JJ
Phytomedicine; 2023 Jul; 116():154898. PubMed ID: 37247590
[TBL] [Abstract][Full Text] [Related]
26. Regulatory T cells and asthma.
Robinson DS
Clin Exp Allergy; 2009 Sep; 39(9):1314-23. PubMed ID: 19538496
[TBL] [Abstract][Full Text] [Related]
27. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment.
Granito A; Muratori L; Lalanne C; Quarneti C; Ferri S; Guidi M; Lenzi M; Muratori P
World J Gastroenterol; 2021 Jun; 27(22):2994-3009. PubMed ID: 34168403
[TBL] [Abstract][Full Text] [Related]
28. Expression of tumor necrosis factor-Ī± induced protein 8 like-2 contributes to the immunosuppressive property of CD4(+)CD25(+) regulatory T cells in mice.
Luan YY; Yao YM; Zhang L; Dong N; Zhang QH; Yu Y; Sheng ZY
Mol Immunol; 2011 Oct; 49(1-2):219-26. PubMed ID: 21963221
[TBL] [Abstract][Full Text] [Related]
29. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
[TBL] [Abstract][Full Text] [Related]
30. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Revenko A; Carnevalli LS; Sinclair C; Johnson B; Peter A; Taylor M; Hettrick L; Chapman M; Klein S; Solanki A; Gattis D; Watt A; Hughes AM; Magiera L; Kar G; Ireland L; Mele DA; Sah V; Singh M; Walton J; Mairesse M; King M; Edbrooke M; Lyne P; Barry ST; Fawell S; Goldberg FW; MacLeod AR
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387780
[TBL] [Abstract][Full Text] [Related]
31. Targeting of TLRs inhibits CD4+ regulatory T cell function and activates lymphocytes in human peripheral blood mononuclear cells.
Voo KS; Bover L; Harline ML; Weng J; Sugimoto N; Liu YJ
J Immunol; 2014 Jul; 193(2):627-34. PubMed ID: 24928999
[TBL] [Abstract][Full Text] [Related]
32. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.
Curtin JF; Candolfi M; Fakhouri TM; Liu C; Alden A; Edwards M; Lowenstein PR; Castro MG
PLoS One; 2008 Apr; 3(4):e1983. PubMed ID: 18431473
[TBL] [Abstract][Full Text] [Related]
33. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.
Schabowsky RH; Madireddi S; Sharma R; Yolcu ES; Shirwan H
Curr Opin Investig Drugs; 2007 Dec; 8(12):1002-8. PubMed ID: 18058571
[TBL] [Abstract][Full Text] [Related]
34. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
35. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.
Togashi Y; Shitara K; Nishikawa H
Nat Rev Clin Oncol; 2019 Jun; 16(6):356-371. PubMed ID: 30705439
[TBL] [Abstract][Full Text] [Related]
36. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the ResponseĀ of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
37. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.
Zhang HH; Mei MH; Fei R; Liao WJ; Wang XY; Qin LL; Wang JH; Wei L; Chen HS
Int J Oncol; 2010 Apr; 36(4):841-8. PubMed ID: 20198327
[TBL] [Abstract][Full Text] [Related]
38. Modulating Treg stability to improve cancer immunotherapy.
Kang JH; Zappasodi R
Trends Cancer; 2023 Nov; 9(11):911-927. PubMed ID: 37598003
[TBL] [Abstract][Full Text] [Related]
39. Regulatory T Cells for More Targeted Immunosuppressive Therapies.
Allos H; Al Dulaijan BS; Choi J; Azzi J
Clin Lab Med; 2019 Mar; 39(1):1-13. PubMed ID: 30709499
[TBL] [Abstract][Full Text] [Related]
40. TNFR2-expressing CD4
He J; Li R; Chen Y; Hu Y; Chen X
Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]